Breaking News Instant updates and real-time market news.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

, IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

07:34
11/30/16
11/30
07:34
11/30/16
07:34

Otonomy names Kathie Bishop as Chief Scientific Officer

Otonomy (OTIC) announced the appointment of Kathie M. Bishop, Ph.D., as chief scientific officer. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. At Ionis Pharmaceuticals (IONS), she led translational research and development of programs in the neurology franchise including SPINRAZAa, a treatment for patients with spinal muscular atrophy that is awaiting regulatory approval. Bishop succeeds Carl LeBel, Ph.D., who had previously announced his retirement. She joins Otonomy from Tioga Pharmaceuticals where she served as chief scientific officer since 2015.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

  • 30

    Nov

  • 03

    Dec

  • 14

    Dec

OTIC Otonomy
$17.75

-0.1 (-0.56%)

05/10/16
PIPR
05/10/16
NO CHANGE
Target $42
PIPR
Overweight
Piper reiterates Overweight on Otonomy amid today's selloff
Piper Jaffray analyst Joshua Schimmer reiterates an Overweight rating on Otonomy amid today's post-earnings pullback. The denial of a J-code for Otoprio is not notable since it is not the appropriate code for the product, Schimmer tells investors in a research note. The analyst is confident that Otpirio will qualify for a C-code. Otiprio may have off-label use opportunities for which a J code may apply, but these are off-label, he adds. Schimmer keeps a $42 price target for the shares.
05/26/16
WBTH
05/26/16
INITIATION
Target $29
WBTH
Buy
Otonomy initiated with a Buy at WallachBeth
Target $29.
10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
Otonomy named top pick at SunTrust
SunTrust analyst Edward Nash named Otonomy as his top pick. The analyst thinks that the company will benefit from strong uptake of its Otiprio drug over the next one to two quarters during peak season for ear tube surgeries. Additionally, he expects the company to report strong data for trials related to the label expansion of Otiprio and its Meniere's disease program. He keeps a $43 price target and Buy rating on the shares.
IONS Ionis Pharmaceuticals
$46.27

0.52 (1.14%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Ionis drug likely to be approved rapidly, says Wells Fargo
After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.
11/01/16
PIPR
11/01/16
NO CHANGE
PIPR
Overweight
Piper sees thrombosis treatment from Ionis as differentiated
Piper Jaffray analyst Joshua Schimmer believes IONS-FXI is differentiated by its "potential utility in renal impairment, infrequent injections and low risk of bleeding complications." Ionis Pharmaceuticals (IONS) and its partner Bayer (BAYRY) reported positive data from a Phase 2 study of IONS-FXI, an anti-clotting antisense therapeutic which targets Factor 11 to prevent thrombosis, Schimmer tells investors in a research note. He views the recent weakness in Ionis shares as a "compelling buying opportunity" and reiterates an Overweight rating on the name.
11/07/16
PIPR
11/07/16
NO CHANGE
PIPR
Biogen, Ionis get jump start on AveXis, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that following his upgrade this morning, Biogen (BIIB) and its partner Ionis Pharmaceuticals (IONS) announced that a Phase III study of nusinersen met its primary endpoint. The data look "very good," Schimmer tells investors in a research note. This gives Biogen and Ionis a jump start on rival gene therapy player AveXis for the Type II/III setting, Schimmer tells investors in a research note. If not for competition from AveXis, nusinersen would become a $5B-plus mega-blockbuster by addressing one of the highest unmet needs in pediatric diseases that exists today, the analyst contends. Schimmer believes, however, that AveXis is moving quickly to compete in the market. The analyst still hopes Biogen "will find a way to partner" with AveXis. He still thinks nusinersen, which is now called SPINRAZA, can achieve $1B-$2B-plus in peak annual revenue. Following this morning's upgrade, Schimmer has an Overweight rating on Biogen with a $335 price target.
11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.

TODAY'S FREE FLY STORIES

08:15
06/22/17
06/22
08:15
06/22/17
08:15
General news
Jobless Claims to be reported at 08:30 »

Week of 6/17 Jobless…

MU

Micron

$32.01

1.18 (3.83%)

08:14
06/22/17
06/22
08:14
06/22/17
08:14
Hot Stocks
Micron appoints Sumit Sadana as Chief Business Officer »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

NVS

Novartis

$82.56

0.96 (1.18%)

08:14
06/22/17
06/22
08:14
06/22/17
08:14
Technical Analysis
Technical View: Novartis at new 52-week high »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

CACI

CACI

$120.85

0.85 (0.71%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Hot Stocks
CACI sees September quarter 'particularly strong in awards, funding' »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ZGNX

Zogenix

$15.00

0.25 (1.69%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Hot Stocks
Zogenix receives ODD from FDA for ZX008 »

Zogenix announced the FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$13.79

0.05 (0.36%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Downgrade
Celestica rating change  »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$37.23

-0.92 (-2.41%)

08:11
06/22/17
06/22
08:11
06/22/17
08:11
Hot Stocks
Nielsen and Trax partner to develop shelf consumer data solution »

Nielsen and Trax, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUNW

Sunworks

$1.56

0.0315 (2.06%)

08:11
06/22/17
06/22
08:11
06/22/17
08:11
Hot Stocks
Sunworks announces new project for 760 KW solar system in Nevada »

Sunworks announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVEE

NV5 Global

$41.45

-0.5 (-1.19%)

08:10
06/22/17
06/22
08:10
06/22/17
08:10
Hot Stocks
NV5 Global awarded $7M contract for Bridge Replacement »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$28.55

0.03 (0.11%)

08:09
06/22/17
06/22
08:09
06/22/17
08:09
Periodicals
Vodafone incorrectly charged 'Red Roaming' customers, Independent says »

Vodafone may face action…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$13.87

0.14 (1.02%)

08:09
06/22/17
06/22
08:09
06/22/17
08:09
Initiation
Del Taco initiated  »

Del Taco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.43

0.4 (0.83%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Technical Analysis
Technical View: American Airlines trades higher in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

QGEN

QIAGEN

$34.83

0.08 (0.23%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Hot Stocks
QIAGEN's QuantiFERON TB test reimbursement approved by French health system »

QIAGEN's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

SNE

Sony

$38.14

-0.02 (-0.05%)

, WWE

WWE

$20.38

0.23 (1.14%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Sony Pictures Networks India, WWE announce WWE Sunday Dhamaal »

Sony Pictures Networks…

SNE

Sony

$38.14

-0.02 (-0.05%)

WWE

WWE

$20.38

0.23 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

GTIM

Good Times Restaurants

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Initiation
Good Times Restaurants initiated  »

Good Times Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.43

0.4 (0.83%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines: Qatar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

KMX

CarMax

$59.74

0.48 (0.81%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Downgrade
CarMax rating change  »

CarMax downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Hot Stocks
American Airlines: Qatar Airways intends to make 'significant' investment »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

ANF

Abercrombie & Fitch

$12.05

-0.16 (-1.31%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Upgrade
Abercrombie & Fitch rating change  »

Correction: Abercrombie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
06/22/17
06/22
08:05
06/22/17
08:05
General news
Treasury Market Outlook: bonds are little changed »

Treasury Market Outlook:…

WFM

Whole Foods

$43.26

0.48 (1.12%)

, KR

Kroger

$22.37

-0.01 (-0.04%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Recommendations
Whole Foods, Kroger, Costco, Target, Wal-Mart, Amazon.com analyst commentary  »

JPMorgan has 'hard…

WFM

Whole Foods

$43.26

0.48 (1.12%)

KR

Kroger

$22.37

-0.01 (-0.04%)

COST

Costco

$163.15

0.25 (0.15%)

TGT

Target

$50.52

-0.39 (-0.77%)

WMT

Wal-Mart

$76.24

0.7 (0.93%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 28

    Jun

  • 23

    Aug

ISBC

Investors Bancorp

$13.08

-0.18 (-1.36%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
Investors Bancorp appoints Michael Fegan Chief Information and Operations Office »

Investors Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JW.A

John Wiley

$51.75

0.4 (0.78%)

, JW.B

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
John Wiley & Sons raises quarterly dividend 3% to 32c per share »

John Wiley & Sons…

JW.A

John Wiley

$51.75

0.4 (0.78%)

JW.B

JWB

John Wiley & Sons; also tag JWA

JWA

John Wiley & Sons; also tag JWB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.